Surgery Partners/$SGRY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Surgery Partners
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
Ticker
$SGRY
Sector
Primary listing
Employees
15,000
Headquarters
Website
Surgery Partners Metrics
BasicAdvanced
$2.8B
-
-$1.43
1.76
-
Price and volume
Market cap
$2.8B
Beta
1.76
52-week high
$32.63
52-week low
$18.87
Average daily volume
1.4M
Financial strength
Current ratio
1.928
Quick ratio
1.418
Long term debt to equity
104.563
Total debt to equity
108.743
Interest coverage (TTM)
1.92%
Profitability
EBITDA (TTM)
644.9
Gross margin (TTM)
23.74%
Net profit margin (TTM)
-5.57%
Operating margin (TTM)
14.96%
Effective tax rate (TTM)
96.58%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
3.92%
Return on equity (TTM)
0.12%
Valuation
Price to revenue (TTM)
0.851
Price to book
1.59
Price to tangible book (TTM)
-0.82
Price to free cash flow (TTM)
15.723
Free cash flow yield (TTM)
6.36%
Free cash flow per share (TTM)
1.386
Growth
Revenue change (TTM)
12.05%
Earnings per share change (TTM)
431.81%
3-year revenue growth (CAGR)
10.78%
10-year revenue growth (CAGR)
16.61%
3-year earnings per share growth (CAGR)
61.17%
What the Analysts think about Surgery Partners
Analyst ratings (Buy, Hold, Sell) for Surgery Partners stock.
Bulls say / Bears say
Second-quarter revenue grew 8.4% year-on-year to $826.2 million, adjusted EBITDA rose 9% to $129.0 million, and the company beat analyst estimates while reaffirming full-year 2025 guidance
Bain Capital’s non-binding proposal to acquire remaining shares at $25.75 per share represented a 21.2% premium and sent SGRY shares up about 17%, underscoring strong intrinsic value
Wall Street consensus remains a “buy” with a median 12-month price target of $33.00, implying roughly 33% upside from recent levels
High leverage with a net debt to EBITDA ratio of approximately 4.1x at the end of Q1 2025, above industry averages and potentially limiting financial flexibility
Operating cash flow plunged to $6.0 million in Q1 2025 from $40.7 million a year earlier, indicating working capital pressures and higher interest costs
Bain Capital’s 21.2% acquisition premium may invite competing higher bids and extend strategic uncertainty for shareholders
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Surgery Partners Financial Performance
Revenues and expenses
Surgery Partners Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Surgery Partners stock?
Surgery Partners (SGRY) has a market cap of $2.8B as of September 18, 2025.
What is the P/E ratio for Surgery Partners stock?
The price to earnings (P/E) ratio for Surgery Partners (SGRY) stock is 0 as of September 18, 2025.
Does Surgery Partners stock pay dividends?
No, Surgery Partners (SGRY) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Surgery Partners dividend payment date?
Surgery Partners (SGRY) stock does not pay dividends to its shareholders.
What is the beta indicator for Surgery Partners?
Surgery Partners (SGRY) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.